A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Trial Profile

A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EU-TREAT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 06 Nov 2017 According to a Novo Nordisk media release, new analysis of real-world data was presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.
    • 13 Jun 2017 Results (n=1717) evaluating the effectiveness of Insulin Degludec after switching from any other basal insulin in patients with type 1 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results (n=833) evaluating the effectiveness of Insulin Degludec after switching from any other basal insulin in patients with type 2 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top